Uncategorized

Celcuity slides even after ‘practice-changing’ late-stage breast cancer data

Published

on

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version